Skip to main content

Peer Review reports

From: Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting

Original Submission
30 Sep 2022 Submitted Original manuscript
9 Oct 2022 Author responded Author comments - xavier Pivot
27 Oct 2022 Author responded Author comments - xavier Pivot
Resubmission - Version 2
9 Oct 2022 Submitted Manuscript version 2
28 Nov 2022 Reviewed Reviewer Report
2 Jan 2023 Reviewed Reviewer Report - Hans-christian Kolberg
5 Jan 2023 Reviewed Reviewer Report
14 Jan 2023 Author responded Author comments - xavier Pivot
Resubmission - Version 3
14 Jan 2023 Submitted Manuscript version 3
18 Jan 2023 Author responded Author comments - xavier Pivot
Resubmission - Version 4
18 Jan 2023 Submitted Manuscript version 4
Publishing
23 Jan 2023 Editorially accepted
31 Jan 2023 Article published 10.1186/s12885-023-10574-2

You can find further information about peer review here.

Back to article page